Compare MMYT & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMYT | TVTX |
|---|---|---|
| Founded | 2000 | N/A |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.3B |
| IPO Year | 2010 | 2013 |
| Metric | MMYT | TVTX |
|---|---|---|
| Price | $60.51 | $65.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $101.00 | $40.62 |
| AVG Volume (30 Days) | 648.5K | ★ 1.6M |
| Earning Date | 05-20-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.83 | $44.76 |
| Revenue Next Year | $17.24 | $35.51 |
| P/E Ratio | $107.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.67 | $17.05 |
| 52 Week High | $103.56 | $66.24 |
| Indicator | MMYT | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.96 | 67.55 |
| Support Level | $53.09 | $53.76 |
| Resistance Level | $60.67 | $66.24 |
| Average True Range (ATR) | 2.17 | 2.47 |
| MACD | -0.22 | 0.41 |
| Stochastic Oscillator | 30.97 | 95.72 |
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.